Indian Drug Makers Increase Nutraceutical Activity
This article was originally published in PharmAsia News
Executive Summary
Several Indian drug makers are expanding their nutraceutical products to take advantage of an expected explosion in the market. The pharmaceutical industry estimates the nutraceutical segment of medicine to be worth about $400 million in India, a major part of a $7 billion health care sector. An Ernst & Young partner questioned, however, whether the segment also should include ayurvedic and herbal products, which in India are considered drugs for regulatory purposes. Those products are expected to reach $190 billion in sales by 2010. Among drug makers seeking to expand are Elder Pharma, Glenmark, Plethico, Troikaa and Wockhardt. (Click here for more
|
Several Indian drug makers are expanding their nutraceutical products to take advantage of an expected explosion in the market. The pharmaceutical industry estimates the nutraceutical segment of medicine to be worth about $400 million in India, a major part of a $7 billion health care sector. An Ernst & Young partner questioned, however, whether the segment also should include ayurvedic and herbal products, which in India are considered drugs for regulatory purposes. Those products are expected to reach $190 billion in sales by 2010. Among drug makers seeking to expand are Elder Pharma, Glenmark, Plethico, Troikaa and Wockhardt. (Click here for more) "Pharma Firms Betting Big On Nutraceuticals" - Economic Times (India) (8/22/08) |